key inclusion criteria: - hospitalized with coronavirus disease 2019 (covid-19) pneumonia confirmed by world health organization criteria. - oxygen saturation ≤ 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen < 300 mm hg and > 200 mm hg. - negative influenza test. - lymphocyte counts < 10^3/μl and the presence of at least one of the following markers of hyperinflammation within 1 day prior to vib7734 administration: - elevated high sensitivity c-reactive protein (hscrp) > 50 mg/l - ferritin > 500 ng/ml - lactate dehydrogenase (ldh) > 300 u/l - d-dimers > 500 ng/ml note: other protocol defined inclusion criteria apply key

key inclusion criteria: - hospitalized with coronavirus disease 2019 (covid-19) pneumonia confirmed by world health organization criteria. - oxygen saturation ≤ 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen < 300 mm hg and > 200 mm hg. - negative influenza test. - lymphocyte counts < 10^3/μl and the presence of at least one of the following markers of hyperinflammation within 1 day prior to vib7734 administration: - elevated high sensitivity c-reactive protein (hscrp) > 50 mg/l - ferritin > 500 ng/ml - lactate dehydrogenase (ldh) > 300 u/l - d-dimers > 500 ng/ml note: other protocol defined inclusion criteria apply key